staurosporine has been researched along with imatinib in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (33.33) | 29.6817 |
2010's | 10 (55.56) | 24.3611 |
2020's | 2 (11.11) | 2.80 |
Authors | Studies |
---|---|
Abe, K; Giese, NA; Hollenbach, SJ; Hutchaleelaha, A; Lambing, JL; Pandey, A; Rose, JW; Scarborough, RM; Seroogy, JM; Volkots, DL; Yu, JC | 1 |
Adams, JM; Atwell, S; Badger, J; Buchanan, MD; Buchanan, SG; Burley, SK; Feil, IK; Froning, KJ; Gao, X; Hendle, J; Keegan, K; Leon, BC; Müller-Dieckmann, HJ; Nienaber, VL; Noland, BW; Post, K; Rajashankar, KR; Ramos, A; Russell, M | 1 |
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW | 1 |
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Li, LL; Ren, JX; Wei, YQ; Xie, HZ; Yang, L; Yang, SY; Zou, J | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Chen, Y; Chu, B; Gong, P; Jiang, Y; Liu, F; Ma, X; Tan, C; Zhai, X; Zhang, C; Zu, X | 1 |
Russu, WA; Shallal, HM | 1 |
Chen, Y; Gao, C; Jiang, Y; Jin, Y; Liu, H; Luan, X; Sun, Q; Tan, C; Zhang, N | 1 |
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K | 1 |
Chen, Y; Gao, D; Jiang, Y; Jin, F; Liu, F; Tan, C; Wu, Q | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Abbe, P; Benhida, R; Cavazza, E; Cerezo, M; Jaune, E; Millet, A; Plaisant, M; Rocchi, S; Ronco, C | 1 |
Cao, T; Ding, Y; Guo, M; Hu, L; Lv, Y; Yang, L; Zhang, Q | 1 |
Bang, EK; El-Damasy, AK; Jin, H; Keum, G; Seo, SH | 1 |
Becker, A; Georg, GI; Hong, KH; Lee, JC; Schönbrunn, E; Tash, JS | 1 |
18 other study(ies) available for staurosporine and imatinib
Article | Year |
---|---|
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Topics: Administration, Oral; Animals; Biological Availability; Dogs; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; In Vitro Techniques; Leukemia, Experimental; Leukemia, Myelomonocytic, Chronic; Macaca fascicularis; Male; Mice; Mice, Nude; Microsomes, Liver; Mutation; Phosphorylation; Piperazines; Plasma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Quinazolines; Rats; Rats, Inbred Lew; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
Topics: Animals; Benzamides; Binding Sites; Catalysis; Catalytic Domain; Crystallography, X-Ray; Enzyme Precursors; Hematopoietic Stem Cells; Humans; Hydrogen Bonding; Imatinib Mesylate; Insecta; Intracellular Signaling Peptides and Proteins; Ligands; Models, Molecular; Mutation; Phosphorylation; Piperazines; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Staurosporine; Syk Kinase; X-Rays | 2004 |
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
Topics: Computer Simulation; Intracellular Signaling Peptides and Proteins; Models, Molecular; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Small Molecule Libraries; Software; Structure-Activity Relationship; Syk Kinase | 2009 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
Topics: Apoptosis; Artificial Intelligence; Drug Discovery; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Humans; K562 Cells; Models, Molecular; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrrolidines; Structure-Activity Relationship; User-Computer Interface | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.
Topics: Acridines; Aminoacridines; Binding Sites; Cell Line, Tumor; Computer Simulation; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; src-Family Kinases; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |
Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Imatinib Mesylate; K562 Cells; Mitogen-Activated Protein Kinase 1; Molecular Docking Simulation; Niacinamide; Piperazines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; Pyrrolidines; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Mice; Pancreatic Neoplasms; Structure-Activity Relationship; Thiazoles | 2016 |
Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
Topics: Benzamides; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Inhibitory Concentration 50; K562 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship | 2016 |
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
Topics: Amination; Antineoplastic Agents; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Protein Kinase Inhibitors | 2020 |
Tetrahydroindazole inhibitors of CDK2/cyclin complexes.
Topics: Binding Sites; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Indazoles; MCF-7 Cells; Molecular Structure; Structure-Activity Relationship | 2021 |